Surgepays, Inc. current report, 12 February 2024

SurgePays, Inc. (SURG) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by SurgePays, Inc., a Nevada corporation, on February 12, 2024. The report details the closing of an over-allotment option related to a public offering of common stock previously initiated on January 22, 2024.

Key Financial Metrics

  • Gross Proceeds from Over-Allotment: Approximately $2.25 million (before underwriting discounts and expenses).
  • Total Gross Proceeds from Offering: Approximately $17.25 million (including the initial sale and full over-allotment exercise).
  • Total Shares Issued and Sold: 3,080,356 shares of common stock.
  • Offering Price: $5.60 per share.
  • Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting underwriting discounts, commissions, and estimated offering expenses.
  • Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.

Material Changes

The primary material change reported is the full exercise of the 45-day over-allotment option by the underwriters. This action increased the total number of shares sold in the offering from 2,678,571 to 3,080,356 and increased total gross proceeds from the initial offering amount to approximately $17.25 million.

Guidance, Outlook, and Risks

The filing text does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard disclosure of the offering mechanics. No unusual items were reported in this specific filing.

Key Facts for Investor Verification

  • Verify the exact amount of underwriting discounts and offering expenses to calculate the net cash proceeds received by the company.
  • Confirm the updated total share count and potential dilution impact on existing shareholders following the issuance of 3,080,356 shares.
  • Review the company's use of proceeds as disclosed in the initial prospectus or related filings to understand capital allocation plans.
  • Monitor the trading volume and price stability of the common stock (SURG) and warrants (SURGW) following the completion of the offering.